M. Whitlow

发表

Large increases in general stability for subtilisin BPN' through incremental changes in the free energy of unfolding.

P. Bryan, K. D. Hardman, M. Pantoliano, 1989, Biochemistry.

Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry.

N. Sigal, D. Auld, M. Adler, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Single-chain antigen-binding proteins.

K. D. Hardman, M. Whitlow, R. Bird, 1988, Science.

A novel, highly stable fold of the immunoglobulin binding domain of streptococcal protein G.

A. Gronenborn, G. Clore, P. Wingfield, 1993, Science.

Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.

M. Adler, M. Whitlow, C. Mallari, 2018, Bioorganic & medicinal chemistry letters.

Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).

M. Adler, M. Whitlow, R. Pulk, 2009, Bioorganic & medicinal chemistry letters.

Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1*

Marc Adler, M. Adler, M. Whitlow, 2005, Journal of Biological Chemistry.

Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

T. Yokota, J. Schlom, M. Whitlow, 1992, Cancer research.

Structures of potent selective peptide mimetics bound to carboxypeptidase B.

M. Adler, M. Whitlow, J. Morser, 2008, Acta crystallographica. Section D, Biological crystallography.

1.67-A X-ray structure of the B2 immunoglobulin-binding domain of streptococcal protein G and comparison to the NMR structure of the B1 domain.

A M Gronenborn, G M Clore, A. Gronenborn, 1992, Biochemistry.

Crystal Structures of Zinc-free and -bound Heme Domain of Human Inducible Nitric-oxide Synthase

T. Poulos, Huiying Li, M. Whitlow, 1999, The Journal of Biological Chemistry.

Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.

M. Adler, M. Whitlow, M. Morrissey, 2007, Bioorganic & medicinal chemistry.

Nuclear magnetic resonance study of the solution structure of alpha 1-purothionin. Sequential resonance assignment, secondary structure and low resolution tertiary structure.

G M Clore, G. Clore, D. Sukumaran, 1987, Journal of molecular biology.

An empirical examination of potential energy minimization using the well-determined structure of the protein crambin

M. Whitlow, M. Teeter, Martha M. Teeter, 1986 .

A-DNA accommodates adducts derived from diol epoxides of polycyclic aromatic hydrocarbons bound in a "side-stacking" mode.

S. Mohr, M. Whitlow, M. Teeter, 1987, Journal of biomolecular structure & dynamics.

An Empirical Examination of Potential Energy Minimization Using the Well-Determined Structure of the Protein Crambin.

M. Whitlow, M. Teeter, 1987 .

Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.

M. Adler, M. Whitlow, R. Feldman, 2007, Bioorganic & medicinal chemistry letters.

Single-chain site-specific mutations of fluorescein-amino acid contact residues in high affinity monoclonal antibody 4-4-20.

M. Whitlow, E. Voss, L. Denzin, 1991, The Journal of biological chemistry.

Construction and characterization of a single-chain catalytic antibody.

R. Gibbs, S. Benkovic, B. Posner, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Potent Triazolothione Inhibitor of Heat‐Shock Protein‐90

M. Adler, M. Whitlow, R. Feldman, 2009, Chemical biology & drug design.

Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.

T. Yokota, J. Schlom, M. Whitlow, 1993, Cancer research.

Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules.

J. D. Yang, M. Whitlow, D. Filpula, 1998, Protein engineering.

Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.

T. Yokota, J. Schlom, M. Whitlow, 1992, Cancer research.

Crystallization of single-chain Fv proteins.

R. Raag, A. Howard, M. Whitlow, 1993, Journal of molecular biology.

1-(1,3-Benzodioxol-5-ylmethyl)-3-[4-(1H-imidazol-1-yl)phenoxy]-piperidine analogs as potent and selective inhibitors of nitric oxide formation.

Wei Xu, M. Adler, M. Whitlow, 2007, Bioorganic & medicinal chemistry letters.

Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.

M. Whitlow, Ying-hua Zhu, M. Polokoff, 2006, Cancer research.

The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.

M. Adler, M. Whitlow, E. Zhang, 2006, Bioorganic & Medicinal Chemistry Letters.

Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.

M. Whitlow, D. Davey, K. Eagen, 1998, Journal of medicinal chemistry.

Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.

Bin Ye, David Light, Marc Adler, 2007, Journal of medicinal chemistry.

Crystal structures of two potent nonamidine inhibitors bound to factor Xa.

Bin Ye, Marc Adler, M. Adler, 2002, Biochemistry.

Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.

Sung-Hou Kim, M. Adler, S. Kim, 2000, Biochemistry.

Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.

A. Beatty, M. Whitlow, D. Davey, 1999, Journal of medicinal chemistry.

Crystallographic analysis of potent and selective factor Xa inhibitors complexed to bovine trypsin.

M. Whitlow, D. Davey, M. Morrissey, 1999, Acta crystallographica. Section D, Biological crystallography.

Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.

M. Whitlow, M. Morrissey, S. Sakata, 2000, Bioorganic & medicinal chemistry letters.

Conformations of trypsin-bound amidine inhibitors of blood coagulant factor Xa by double REDOR NMR and MD simulations.

M. Whitlow, M. McCarrick, J. Schaefer, 1999, Journal of medicinal chemistry.

Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.

M. Whitlow, M. Morrissey, M. McCarrick, 1999, Journal of medicinal chemistry.

A model of the acid sphingomyelinase phosphoesterase domain based on its remote structural homolog purple acid phosphatase

S. Srinivasan, M. Whitlow, R. Mintzer, 2004, Protein science : a publication of the Protein Society.

based on its remote structural homolog purple acid phosphatase A model of the acid sphingomyelinase phosphoesterase domain data

S. Srinivasan, M. Whitlow, R. Mintzer, 2004 .

X-ray Crystallographic Studies of Candida albicans Dihydrofolate Reductase

L. Kuyper, D. Baccanari, K. D. Hardman, 1997, The Journal of Biological Chemistry.

Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase.

J. Haeggström, M. Adler, M. Whitlow, 2008, Bioorganic & medicinal chemistry.

Single chain antigen binding protein (sFv CC49)

S. Larson, J. Schlom, Jiaju Zhang, 1997, Cancer.

A metal‐mediated hydride shift mechanism for xylose isomerase based on the 1.6 Å Streptomycs rubiginosus structure with xylitol and D‐xylose

T. Poulos, E. Winborne, G. Gilliland, 1991, Proteins.

Engineering subtilisin for reaction in dimethylformamide

Chi‐Huey Wong, M. Whitlow, M. Rollence, 1991 .

Enzymes in organic synthesis: use of subtilisin and a highly stable mutant derived from multiple site-specific mutations

P. Bryan, Chi‐Huey Wong, M. Pantoliano, 1990 .

Single-chain Fv proteins and their fusion proteins

M. Whitlow, D. Filpula, 1991 .

The engineering of binding affinity at metal ion binding sites for the stabilization of proteins: subtilisin as a test case.

T. Poulos, P. Bryan, G. Gilliland, 1988, Biochemistry.

Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.

M. Adler, M. Whitlow, R. Feldman, 2007, Bioorganic & medicinal chemistry letters.

Single‐chain Fvs

R. Raag, M. Whitlow, M Whitlow, 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.

K. D. Hardman, J. Schlom, M. Whitlow, 1993, Protein engineering.

Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences.

M. Whitlow, M. Benasutti, E. Loechler, 1988, Biochemistry.

Mapping the binding site of aflatoxin B1 in DNA: molecular modeling of the binding sites for the N(7)-guanine adduct of aflatoxin B1 in different DNA sequences.

M. Whitlow, M. Teeter, E. Loechler, 1988, Journal of biomolecular structure & dynamics.

Homology model of human interferon‐α8 and its receptor complex

M. Adler, M. Whitlow, E. Croze, 1995 .

Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds.

M. Whitlow, D. Filpula, C. Shi, 1999, Bioconjugate chemistry.

Protein fold analysis of the B30.2‐like domain

M. Whitlow, D. Zajchowski, Hsiao-Lai Liu, 1999, Proteins.

Energy minimization for tertiary structure prediction of homologous proteins: alpha 1-purothionin and viscotoxin A3 models from crambin.

M. Whitlow, M. Teeter, 1985, Journal of biomolecular structure & dynamics.

Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

T. Yokota, J. Schlom, M. Whitlow, 1991, Cancer research.

Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B.

M. Adler, M. Whitlow, I. Islam, 2005, Biochemistry.

Engineering a Stable Protease

P. Bryan, K. D. Hardman, M. Pantoliano, 1988 .

Crystal structure of a protein‐toxin α1‐purothionin at 2.5Å and a comparison with predicted models

M. Whitlow, M. Teeter, Xing-qi Ma, 1990, Proteins.

The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex*

A. Gils, M. Whitlow, P. Declerck, 2009, Journal of Biological Chemistry.

3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).

M. Adler, M. Whitlow, R. Vergona, 2007, Bioorganic & medicinal chemistry letters.

Mechanistic Studies with Potent and Selective Inducible Nitric-oxide Synthase Dimerization Inhibitors*

Sanjay Ghosh, Douglas S. Auld, Wei Xia, 2002, The Journal of Biological Chemistry.

Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv.

M. Whitlow, J. Wood, M. Rollence, 1994, Protein engineering.

ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution.

S. Bass, M. Whitlow, Qian Zhang, 2016, Protein engineering, design & selection : PEDS.

1.85 A structure of anti-fluorescein 4-4-20 Fab.

K. D. Hardman, A. Howard, M. Whitlow, 1995, Protein engineering.

Structure of human plasminogen kringle 4 at 1.68 a and 277 K. A possible structural role of disordered residues.

B. Stec, M. Whitlow, M. Teeter, 1997, Acta crystallographica. Section D, Biological crystallography.

Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors.

M. Adler, M. Whitlow, M. Ohlmeyer, 2007, Journal of medicinal chemistry.

Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.

M. Whitlow, D. Arnaiz, L. Trinh, 2000, Bioorganic & medicinal chemistry letters.

Test of circular dichroism (CD) methods for crambin and CD‐assisted secondary structure prediction of its homologous toxins

M. Whitlow, M. Teeter, 1988, Proteins.

The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2.

M. Adler, M. Whitlow, E. Zhang, 2005, Bioorganic & medicinal chemistry letters.